In Brief: Bard
This article was originally published in The Gray Sheet
Executive Summary
Bard: Medical division commences marketing in the North American hospital and home health markets ProCyte's line of acute and extended-care wound care products, including Iamin hydrating gel, Iamin wound cleanser and OsmoCyte pillow wound dressings. Redmond, Washington-based ProCyte reported in August at the Medical Investments Northwest conference in Seattle that the firm was actively seeking a marketing partner for its Iamin wound care gel ("The Gray Sheet" Aug. 25, I&W-6), which has been marketed by ProCyte since July 1996. The hydrogel is indicated for treating diabetic, venous or mixed etilogy leg ulcers, pressure sores, first and second-degree burns, donor sites and surgical wounds. OsmoCyte is indicated for the exudation of an array of dermal wounds. Terms of the deal call for Bard to purchase on an annual basis a minimum amount of devices from ProCyte, which retains rights to sell the products in the North American dermatology and cosmetic surgery markets...